# A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

> **NCT07143968** · PHASE2 · RECRUITING · sponsor: **Naga P. Chalasani** · enrollment: 120 (estimated)

## Conditions studied

- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- HIV (Human Immunodeficiency Virus)

## Interventions

- **DRUG:** Resmetirom
- **DRUG:** Placebo Control

## Key facts

- **NCT ID:** NCT07143968
- **Lead sponsor:** Naga P. Chalasani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-23
- **Primary completion:** 2027-10
- **Final completion:** 2027-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07143968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07143968, "A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07143968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*